DCTD Programs
Last Updated: 08/14/2023
Apply for Grants
The Division of Cancer Treatment and Diagnosis funds a large portfolio of grants and contracts. Here we provide a listing of funding opportunities that are accepting applications. Please visit this page regularly, as new funding opportunities are added upon approval by NCI.
**Important DCTD Grantsmanship Resources**
Awaiting Receipt of Applications (ARAs) for Large Budget Grant Applications
Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas
Funding Opportunities through DCTD’s Programs
Visit the websites of DCTD's individual programs for more information on available funding opportunities.
- Cancer Diagnosis Program
- Cancer Imaging Program
- Cancer Therapy Evaluation Program
- Developmental Therapeutics Program
- Radiation Research Program
- Translational Research Program
- Office of Cancer Complementary and Alternative Medicine
Title | Announcement Number | Expiration Date | Activity Code |
---|---|---|---|
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-20-313; PAR-20-314 |
October 11, 2023 | UH2/H3 |
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed) | PAR-23-088 | October 28, 2023 | R01 |
Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (Clinical Trial Not Allowed) | RFA-CA-23-036 | November 16, 2023 | U01 |
Next Generation Chemistry Centers for Fusion Oncoproteins (Clinical Trial Not Allowed) | RFA-CA-23-037 | November 16, 2023 | UM1 |
Targeted Fusion Oncoproteins in Childhood Cancers Network Pre-Application Webinar for RFA-CA-23-036 and RFA-CA-23-037 | |||
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-21-033 | January 8, 2024 | R01 |
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (Clinical Trial Not Allowed) | PAR-21-166 | January 8, 2024 | R01 |
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Not Allowed) | PAR-22-090 | January 8, 2025 | R21 |
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Optional) | PAR-22-091 | January 8, 2025 | R21 |
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | PAR-22-123 | January 8, 2025 | U01 |
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) | PAR-22-114 | January 24, 2025 | Admin Suppl |
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | PAR-22-099 | May 8, 2025 | R01 |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed) | PAR-22-086 | May 8, 2025 | R21 |
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed) | PAR-22-085 | May 8, 2025 | R01 |
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (Clinical Trial Not Allowed) | PAR-22-139 | May 8, 2025 | R01 |
Systematic Testing of Radionuclides in Preclinical Experiments (Clinical Trial Not Allowed) | PAR-22-140 | May 8, 2025 | R21 |
NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional) | PAR-22-216 | July 2, 2025 | R21 |
Imaging, biomarkers and digital pathomics for the early detection of premetastatic cancer and precancerous lesions associated with lethal phenotypes (Clinical Trial Optional) | PAR-22-131 | September 8, 2025 | R01 |
Bioengineering Research Grants (Clinical Trial Optional) | PAR-22-243 | September 8, 2025 | R01 |
Bioengineering Research Grants (Clinical Trial Not Allowed) | PAR-22-242 | September 8, 2025 | R01 |
Coinfection and Cancer (Clinical Trial Not Allowed) | PAR-23-056 | November 17, 2025 | R21 |
Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed) | PAR-23-246 | May 5, 2026 | R01 |
Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (Clinical Trial Not Allowed) | PAR-23-264 | September 8, 2026 | R01 |
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (Clinical Trials Optional) | PAR-23-259 | January 8, 2027 | R01 |
DCTD Grantsmanship Resources
- Awaiting Receipt of Applications (ARAs) for Large Budget Grant
- Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas
NCI Grantsmanship Resources
- NCI-wide Funding
- NCI Office of Grants Administration
- NCI Division of Extramural Activities
- The NCI Grants Process
- Guidelines and Tools for Clinical Protocol Development
NIH Grantsmanship Resources
- NIH Parent Announcements
- Office of Extramural Research
- Grant Application Basics
- Center for Scientific Review
- Small Business Funding Opportunities
- New and Early Stage Investigator Policies